

MAINTENANCE THERAPY PRESCRIPTION FORM

JPD-072726-A04

Fax: 1-800-839-7606

Call: 1-888-817-4847

Mon-Fri 8AM-8PM ET

For patients already enrolled in JUVMO Complete: Use this form for new prescriptions or dose adjustments.

For new patients: Use the JUVMO Complete Enrollment and Prescription Form.

1. PATIENT INFORMATION

		MONTH	DAY	YEAR
		/	/	
First Name*	Last Name*	Date of Birth*		
Sex:*	Primary Phone #*	Mobile Phone # (if different)	Email	
☐ Male				
☐ Female	Address*	City*	State*	Zip*

Patient Privacy Notice: For information on how we collect and process patient personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit <https://abbv.ie/PrivacyPatient>

2. PRESCRIBER INFORMATION

Prescriber First Name*	Prescriber Last Name*	Prescriber Title	Prescribing License #	NPI #*	Tax ID #
Prescriber Address*		City*	State*	Zip*	
Office Phone #*	Office Fax #*	Office Contact Name	Office Contact Email		

Prescriber Privacy Notice: For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit <https://abbv.ie/PrivacyHCP>

3. PRESCRIPTION INFORMATION

Prescriber certification: I certify that the below therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed JUVMO to the previously identified patient and that I provided the patient with a description of the JUVMO Complete patient support program. I authorize JUVMO Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan (if applicable). I further request that JUVMO Complete proceed with benefit verification, pharmacy triage, and service communications as part of JUVMO Complete. I understand in the absence of a separately signed patient/caregiver HIPAA authorization, no Protected Health Information (PHI) will be returned to me from a specialty pharmacy. **For states that do not allow dual prescriptions or that have specific prescription requirements, please include a separate prescription when faxing the enrollment form. Please see Prescribing Information for dose modifications for CYP3A inducers and inhibitors.**

Prescriber note: Dose may be titrated upward in 5 mg increments, approximately every 15 days, up to a maximum dose of 15 mg/day.

Select only one strength per prescription.

☐ JUVMO 5 mg tablets☐ JUVMO 10 mg tablets☐ JUVMO 15 mg tablets

Directions:* Take 1 tablet by mouth once daily _____

Qty:* _____ **Refills:*** _____

☐ Brand Medically Necessary/Dispense As Written/DAW/Do Not Substitute/May Not Substitute/No Substitution

☐ May Substitute/Product Selection Permitted/Substitution Permissible/ Substitution Permitted

Prescriber Signature* _____ Date* ____/____/____

INDICATION¹

JUVMO is indicated for the treatment of Parkinson's disease in adults.

SAFETY CONSIDERATIONS¹

JUVMO may cause **hypotension/orthostatic hypotension**; compulsive behavior or **problems with impulse control**; **hallucinations and psychotic-like behavior**; or **dyskinesia**. The **most common adverse reactions (≥5%) for JUVMO without levodopa** were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety. The **most common adverse reactions (≥5%) for JUVMO with levodopa** were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.

Please see additional Important Safety Information on next page.

Please see full [Prescribing Information](https://www.rxabbvie.com/pdf/juvmo_pi.pdf) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.

INDICATION¹

JUVMO is indicated for the treatment of Parkinson's disease in adults.

IMPORTANT SAFETY INFORMATION¹

Warnings and Precautions

Hypotension/Orthostatic Hypotension: Patients with Parkinson's disease (PD) may have an impaired capacity to respond to an orthostatic challenge. In clinical studies and clinical experience, dopaminergic medications appear to impair the systemic regulation of blood pressure, resulting in hypotension and/or orthostatic hypotension, especially during dose escalation. Patients with PD treated with JUVMO (tavapadon) should be monitored for signs and symptoms of hypotension/orthostatic hypotension, especially during dose escalation, and should be informed of this risk.

Impulse Control/Compulsive Behaviors: Patients may experience intense urges while on JUVMO. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while on JUVMO. Consider reducing the dose or discontinuing JUVMO if a patient develops such urges.

Hallucinations and Psychotic-like Behavior: Medications for the treatment of PD, including JUVMO, can have effects on thinking and behavior. Age appears to increase the risk of hallucinations in patients taking JUVMO. The risk of hallucination may be increased when JUVMO is co-administered with strong CYP3A inhibitors during the maintenance phase. Consider the risks and benefits prior to initiating treatment with JUVMO in patients with a major psychotic disorder because of the risk of exacerbating psychosis. Consider stopping JUVMO if hallucinations or psychotic-like behaviors occur.

Dyskinesia: JUVMO may cause or exacerbate pre-existing dyskinesia. Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.

Adverse Reactions

The most common adverse reactions ($\geq 5\%$) for JUVMO without levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety.

The most common adverse reactions ($\geq 5\%$) for JUVMO with levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.

Drug Interactions

Strong CYP3A Inducers: Avoid use with JUVMO. **Strong and moderate CYP3A inhibitors:** avoid use with JUVMO during titration; JUVMO dosage modification is recommended during maintenance. **Moderate CYP3A Inducers:** JUVMO dosage modification is recommended during titration and maintenance. **Consult the full Prescribing Information for JUVMO** for more information on drug interactions and recommended dosage modifications.

Dosage Forms and Strengths

JUVMO is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.

Please see full [Prescribing Information](https://www.rxabbvie.com/pdf/juvmo_pi.pdf) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.

Reference: 1. JUVMO [package insert]. North Chicago, IL: AbbVie Inc.